Dr Iain Macpherson

  • Clinical Senior Lecturer in Medical Oncology (Clinical Trials Research)

Research interests

Grants
  • Rab-coupling protein (RCP)-mediated receptor trafficking in breast cancer progression.
    Breast Cancer Campaign, BICR
    2013 – 2016

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Scottish Cancer Trials Breast Group Fund
    University of Dundee
    2018 - 2022
     
  • Glasgow ECMC
    Cancer Research UK
    2017 - 2019
     
  • Glasgow ECMC
    Chief Scientist Office
    2017 - 2018
     
  • A RCT using serial cardiac troponin I measurements to guide angiotensin converting enzyme inhibitor and beta blocker treatment to prevent cardiac toxicity in breast cancer patients
    National Institute for Health Research
    2017 - 2020
     
  • OPTIMA main trial
    National Institute for Health Research
    2015 - 2023
     
  • A Phase II Randomized, Double-Blind Study of Neoadjuvunt Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-Positive/HER2-Negative, Early Stage Breast Cancer
    F. Hoffmann-La Roche
    2015 - 2018
     
  • Endocytic Trafficking and Response to Therapy in HER2+ve Breast Cancer
    NHS Greater Glasgow and Clyde Endowment Funds
    2014 - 2015
     
  • Chemotherapy-induced Cellular Senescene in Breast Carcinoma: a pilot project
    NHS Greater Glasgow and Clyde Endowment Funds
    2012 - 2014
     

Publications

List by: Type | Date

Jump to: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2010 | 2009 | 2008 | 2007 | 2006 | 2004 | 2003
Number of items: 36.

2018

Copson, E. et al. (2018) The presentation, management and outcome of inflammatory breast cancer cases in the UK: data from a multi-centre retrospective review. Breast, 42, pp. 133-141. (doi:10.1016/j.breast.2018.09.003) (PMID:30278369)

Novo, D. et al. (2018) Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 9, 5069. (doi:10.1038/s41467-018-07339-y) (PMID:30498210) (PMCID:PMC6265295)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R. and Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), pp. 293-306. (doi:10.1093/toxsci/kfy035) (PMID:29462473) (PMCID:PMC5920327)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) The NTOX-G12- A New Clinical Assessment Tool for Nail Problems as a Result of Taxane Chemotherapy Regimens. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) Taxane Chemotherapy and Nail Toxicity in Women with Breast Cancer: An Evaluation of Interventions. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

2017

Dornier, E. et al. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 8(1), 2255. (doi:10.1038/s41467-017-02101-2) (PMID:29269878) (PMCID:PMC5740148)

Hall, P. S. et al. (2017) Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value in Health, 20(10), pp. 1311-1318. (doi:10.1016/j.jval.2017.04.021) (PMID:29241890)

Cain, H., MacPherson, I.R. , Beresford, M., Pinder, S.E., Pong, J. and Dixon, J.M. (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clinical Oncology, 29(10), pp. 642-652. (doi:10.1016/j.clon.2017.06.003) (PMID:28669449)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi:10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Diaz-Vera, J., Palmer, S., Hernandez-Fernaud, J. R., Dornier, E., Mitchell, L. E., MacPherson, I. , Edwards, J. , Zanivan, S. and Norman, J. C. (2017) A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 130(4), pp. 697-711. (doi:10.1242/jcs.190835) (PMID:28062852)

2016

Kristeleit, H., Parton, M., Beresford, M., Macpherson, I. R. , Sharma, R., Lazarus, L. and Kelleher, M. (2016) Long-term follow-up data from pivotal studies of adjuvant trastuzumab in early breast cancer. Targeted Oncology, 11(5), pp. 579-591. (doi:10.1007/s11523-016-0438-5) (PMID:27181019) (PMCID:PMC5054055)

Bartlett, J. M. S. et al. (2016) Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. Journal of the National Cancer Institute, 108(9), djw050. (doi:10.1093/jnci/djw050) (PMID:27130929)

Marshall-Mckenna, R. , Morrison, A., Stirling, L., Hutchison, C., Rice, A.M., Hewitt, C., Paul, L., Rodger, M., MacPherson, I. and McCartney, E. (2016) A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Supportive Care in Cancer, 24(4), pp. 1821-1829. (doi:10.1007/s00520-015-2967-3) (PMID:26446702)

Palmieri, C. et al. (2016) Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget, 7(11), pp. 13209-13220. (doi:10.18632/oncotarget.4801) (PMID:26334099)

2015

Argilés, G. et al. (2015) Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. European Journal of Cancer, 51(8), pp. 942-949. (doi:10.1016/j.ejca.2015.02.013) (PMID:25818084)

2014

Hickish, T. et al. (2014) A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50(18), pp. 3136-3144. (doi:10.1016/j.ejca.2014.08.008) (PMID:25441408)

MacPherson, I. R. et al. (2014) CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 127(18), pp. 3893-3901. (doi:10.1242/jcs.135947) (PMID:25015290)

Macpherson, I.R. , Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi:10.1016/j.clbc.2014.09.009) (PMID:25454689)

Shepherd, S. T.C., Gillen, G., Morrison, P., Forte, C., MacPherson, I. R. , White, J. D. and Mark, P. B. (2014) Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. European Journal of Cancer, 50(5), pp. 944-952. (doi:10.1016/j.ejca.2013.12.021)

Macagno, J. P., Diaz Vera, J., Yu, Y., MacPherson, I. , Sandilands, E., Palmer, R., Norman, J. C. , Frame, M. and Vidal, M. (2014) FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genetics, 10(3), e1004262. (doi:10.1371/journal.pgen.1004262)

Shepherd, S. T.C., Macpherson, I. R. , White, J. D. and Mark, P. B. (2014) Response to: ‘Letter to the editor, European Journal of Cancer’, commenting on ‘Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma’. European Journal of Cancer, 25(7), pp. 1497-1503. (doi:10.1016/j.ejca.2014.04.027)

2013

Macpherson, I.R. , Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A. and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49(4), pp. 782-789. (doi:10.1016/j.ejca.2012.09.036)

2012

Yu, X. et al. (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 199(3), pp. 527-544. (doi:10.1083/jcb.201203025)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi:10.1016/j.devcel.2011.11.008)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12(536), (doi:10.1186/1471-2407-12-536)

2010

MacPherson, I.R.J. , Lindsay, C. and Canney, P. (2010) Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer: Targets and Therapy, 2010(2), pp. 59-70. (doi:10.2147/BCTT.S11835)

2009

Demetri, G. D., Lo Russo, P., MacPherson, I. R.J. , Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agarwal, S., Voi, M. and Evans, T.R. J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15(9), pp. 6232-6240. (doi:10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J. and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009(1), pp. 1-18. (doi:10.2147/BCTT.S6127)

Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi:10.2217/FON.09.18)

MacPherson, I.R.J. , Lindsay, C.R. and Reed, N.S. (2009) Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. Therapeutics and Clinical Risk Management, 2009(5), pp. 261-270. (doi:10.2147/TCRM.S3320)

2008

MacPherson, I. and Cassidy, J. (2008) Challenges in combinational oncology studies. Pharmaceutical Medicine, 22(2), pp. 85-97.

2007

MacPherson, I. , Hooper, S., Serrels, A., McGarry, L., Ozanne, B., Harrington, K., Frame, M., Sahai, E. and Brunton, V. (2007) p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. Oncogene, 26(36), pp. 5214-5228. (doi:10.1038/sj.onc.1210334)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi:10.2174/1874079000701010009)

2006

Serrels, A., MacPherson, I.R.J. , Evans, T.R.J. , Lee, F.Y., Clark, E.A., Sansom, O.J. , Ashton, G.H., Frame, M.C. and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5(12), pp. 3014-3022. (doi:10.1158/1535-7163.MCT-06-0382)

2004

Brunton, V.G., MacPherson, I.R.J. and Frame, M.C. (2004) Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochimica et Biophysica Acta: Molecular Cell Research, 1692(02-Mar), pp. 121-144. (doi:10.1016/j.bbamcr.2004.04.010)

2003

White, J., MacPherson, I. and Evans, T. (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10(1), pp. 249-251.

This list was generated on Sun Dec 16 16:53:18 2018 GMT.
Number of items: 36.

Articles

Copson, E. et al. (2018) The presentation, management and outcome of inflammatory breast cancer cases in the UK: data from a multi-centre retrospective review. Breast, 42, pp. 133-141. (doi:10.1016/j.breast.2018.09.003) (PMID:30278369)

Novo, D. et al. (2018) Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 9, 5069. (doi:10.1038/s41467-018-07339-y) (PMID:30498210) (PMCID:PMC6265295)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R. and Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), pp. 293-306. (doi:10.1093/toxsci/kfy035) (PMID:29462473) (PMCID:PMC5920327)

Dornier, E. et al. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 8(1), 2255. (doi:10.1038/s41467-017-02101-2) (PMID:29269878) (PMCID:PMC5740148)

Hall, P. S. et al. (2017) Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value in Health, 20(10), pp. 1311-1318. (doi:10.1016/j.jval.2017.04.021) (PMID:29241890)

Cain, H., MacPherson, I.R. , Beresford, M., Pinder, S.E., Pong, J. and Dixon, J.M. (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clinical Oncology, 29(10), pp. 642-652. (doi:10.1016/j.clon.2017.06.003) (PMID:28669449)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi:10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Diaz-Vera, J., Palmer, S., Hernandez-Fernaud, J. R., Dornier, E., Mitchell, L. E., MacPherson, I. , Edwards, J. , Zanivan, S. and Norman, J. C. (2017) A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 130(4), pp. 697-711. (doi:10.1242/jcs.190835) (PMID:28062852)

Kristeleit, H., Parton, M., Beresford, M., Macpherson, I. R. , Sharma, R., Lazarus, L. and Kelleher, M. (2016) Long-term follow-up data from pivotal studies of adjuvant trastuzumab in early breast cancer. Targeted Oncology, 11(5), pp. 579-591. (doi:10.1007/s11523-016-0438-5) (PMID:27181019) (PMCID:PMC5054055)

Bartlett, J. M. S. et al. (2016) Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. Journal of the National Cancer Institute, 108(9), djw050. (doi:10.1093/jnci/djw050) (PMID:27130929)

Marshall-Mckenna, R. , Morrison, A., Stirling, L., Hutchison, C., Rice, A.M., Hewitt, C., Paul, L., Rodger, M., MacPherson, I. and McCartney, E. (2016) A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Supportive Care in Cancer, 24(4), pp. 1821-1829. (doi:10.1007/s00520-015-2967-3) (PMID:26446702)

Palmieri, C. et al. (2016) Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget, 7(11), pp. 13209-13220. (doi:10.18632/oncotarget.4801) (PMID:26334099)

Argilés, G. et al. (2015) Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. European Journal of Cancer, 51(8), pp. 942-949. (doi:10.1016/j.ejca.2015.02.013) (PMID:25818084)

Hickish, T. et al. (2014) A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50(18), pp. 3136-3144. (doi:10.1016/j.ejca.2014.08.008) (PMID:25441408)

MacPherson, I. R. et al. (2014) CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 127(18), pp. 3893-3901. (doi:10.1242/jcs.135947) (PMID:25015290)

Macpherson, I.R. , Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi:10.1016/j.clbc.2014.09.009) (PMID:25454689)

Shepherd, S. T.C., Gillen, G., Morrison, P., Forte, C., MacPherson, I. R. , White, J. D. and Mark, P. B. (2014) Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. European Journal of Cancer, 50(5), pp. 944-952. (doi:10.1016/j.ejca.2013.12.021)

Macagno, J. P., Diaz Vera, J., Yu, Y., MacPherson, I. , Sandilands, E., Palmer, R., Norman, J. C. , Frame, M. and Vidal, M. (2014) FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genetics, 10(3), e1004262. (doi:10.1371/journal.pgen.1004262)

Shepherd, S. T.C., Macpherson, I. R. , White, J. D. and Mark, P. B. (2014) Response to: ‘Letter to the editor, European Journal of Cancer’, commenting on ‘Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma’. European Journal of Cancer, 25(7), pp. 1497-1503. (doi:10.1016/j.ejca.2014.04.027)

Macpherson, I.R. , Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A. and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49(4), pp. 782-789. (doi:10.1016/j.ejca.2012.09.036)

Yu, X. et al. (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 199(3), pp. 527-544. (doi:10.1083/jcb.201203025)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi:10.1016/j.devcel.2011.11.008)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12(536), (doi:10.1186/1471-2407-12-536)

MacPherson, I.R.J. , Lindsay, C. and Canney, P. (2010) Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer: Targets and Therapy, 2010(2), pp. 59-70. (doi:10.2147/BCTT.S11835)

Demetri, G. D., Lo Russo, P., MacPherson, I. R.J. , Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agarwal, S., Voi, M. and Evans, T.R. J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15(9), pp. 6232-6240. (doi:10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J. and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009(1), pp. 1-18. (doi:10.2147/BCTT.S6127)

Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi:10.2217/FON.09.18)

MacPherson, I.R.J. , Lindsay, C.R. and Reed, N.S. (2009) Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. Therapeutics and Clinical Risk Management, 2009(5), pp. 261-270. (doi:10.2147/TCRM.S3320)

MacPherson, I. and Cassidy, J. (2008) Challenges in combinational oncology studies. Pharmaceutical Medicine, 22(2), pp. 85-97.

MacPherson, I. , Hooper, S., Serrels, A., McGarry, L., Ozanne, B., Harrington, K., Frame, M., Sahai, E. and Brunton, V. (2007) p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. Oncogene, 26(36), pp. 5214-5228. (doi:10.1038/sj.onc.1210334)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi:10.2174/1874079000701010009)

Serrels, A., MacPherson, I.R.J. , Evans, T.R.J. , Lee, F.Y., Clark, E.A., Sansom, O.J. , Ashton, G.H., Frame, M.C. and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5(12), pp. 3014-3022. (doi:10.1158/1535-7163.MCT-06-0382)

Brunton, V.G., MacPherson, I.R.J. and Frame, M.C. (2004) Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochimica et Biophysica Acta: Molecular Cell Research, 1692(02-Mar), pp. 121-144. (doi:10.1016/j.bbamcr.2004.04.010)

White, J., MacPherson, I. and Evans, T. (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10(1), pp. 249-251.

Conference or Workshop Item

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) The NTOX-G12- A New Clinical Assessment Tool for Nail Problems as a Result of Taxane Chemotherapy Regimens. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) Taxane Chemotherapy and Nail Toxicity in Women with Breast Cancer: An Evaluation of Interventions. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

This list was generated on Sun Dec 16 16:53:18 2018 GMT.


Dr Iain Macpherson

  • Clinical Senior Lecturer in Medical Oncology (Clinical Trials Research)

Research interests

Grants
  • Rab-coupling protein (RCP)-mediated receptor trafficking in breast cancer progression.
    Breast Cancer Campaign, BICR
    2013 – 2016

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Scottish Cancer Trials Breast Group Fund
    University of Dundee
    2018 - 2022
     
  • Glasgow ECMC
    Cancer Research UK
    2017 - 2019
     
  • Glasgow ECMC
    Chief Scientist Office
    2017 - 2018
     
  • A RCT using serial cardiac troponin I measurements to guide angiotensin converting enzyme inhibitor and beta blocker treatment to prevent cardiac toxicity in breast cancer patients
    National Institute for Health Research
    2017 - 2020
     
  • OPTIMA main trial
    National Institute for Health Research
    2015 - 2023
     
  • A Phase II Randomized, Double-Blind Study of Neoadjuvunt Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-Positive/HER2-Negative, Early Stage Breast Cancer
    F. Hoffmann-La Roche
    2015 - 2018
     
  • Endocytic Trafficking and Response to Therapy in HER2+ve Breast Cancer
    NHS Greater Glasgow and Clyde Endowment Funds
    2014 - 2015
     
  • Chemotherapy-induced Cellular Senescene in Breast Carcinoma: a pilot project
    NHS Greater Glasgow and Clyde Endowment Funds
    2012 - 2014
     

Publications

List by: Type | Date

Jump to: 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2010 | 2009 | 2008 | 2007 | 2006 | 2004 | 2003
Number of items: 36.

2018

Copson, E. et al. (2018) The presentation, management and outcome of inflammatory breast cancer cases in the UK: data from a multi-centre retrospective review. Breast, 42, pp. 133-141. (doi:10.1016/j.breast.2018.09.003) (PMID:30278369)

Novo, D. et al. (2018) Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 9, 5069. (doi:10.1038/s41467-018-07339-y) (PMID:30498210) (PMCID:PMC6265295)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R. and Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), pp. 293-306. (doi:10.1093/toxsci/kfy035) (PMID:29462473) (PMCID:PMC5920327)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) The NTOX-G12- A New Clinical Assessment Tool for Nail Problems as a Result of Taxane Chemotherapy Regimens. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) Taxane Chemotherapy and Nail Toxicity in Women with Breast Cancer: An Evaluation of Interventions. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

2017

Dornier, E. et al. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 8(1), 2255. (doi:10.1038/s41467-017-02101-2) (PMID:29269878) (PMCID:PMC5740148)

Hall, P. S. et al. (2017) Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value in Health, 20(10), pp. 1311-1318. (doi:10.1016/j.jval.2017.04.021) (PMID:29241890)

Cain, H., MacPherson, I.R. , Beresford, M., Pinder, S.E., Pong, J. and Dixon, J.M. (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clinical Oncology, 29(10), pp. 642-652. (doi:10.1016/j.clon.2017.06.003) (PMID:28669449)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi:10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Diaz-Vera, J., Palmer, S., Hernandez-Fernaud, J. R., Dornier, E., Mitchell, L. E., MacPherson, I. , Edwards, J. , Zanivan, S. and Norman, J. C. (2017) A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 130(4), pp. 697-711. (doi:10.1242/jcs.190835) (PMID:28062852)

2016

Kristeleit, H., Parton, M., Beresford, M., Macpherson, I. R. , Sharma, R., Lazarus, L. and Kelleher, M. (2016) Long-term follow-up data from pivotal studies of adjuvant trastuzumab in early breast cancer. Targeted Oncology, 11(5), pp. 579-591. (doi:10.1007/s11523-016-0438-5) (PMID:27181019) (PMCID:PMC5054055)

Bartlett, J. M. S. et al. (2016) Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. Journal of the National Cancer Institute, 108(9), djw050. (doi:10.1093/jnci/djw050) (PMID:27130929)

Marshall-Mckenna, R. , Morrison, A., Stirling, L., Hutchison, C., Rice, A.M., Hewitt, C., Paul, L., Rodger, M., MacPherson, I. and McCartney, E. (2016) A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Supportive Care in Cancer, 24(4), pp. 1821-1829. (doi:10.1007/s00520-015-2967-3) (PMID:26446702)

Palmieri, C. et al. (2016) Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget, 7(11), pp. 13209-13220. (doi:10.18632/oncotarget.4801) (PMID:26334099)

2015

Argilés, G. et al. (2015) Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. European Journal of Cancer, 51(8), pp. 942-949. (doi:10.1016/j.ejca.2015.02.013) (PMID:25818084)

2014

Hickish, T. et al. (2014) A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50(18), pp. 3136-3144. (doi:10.1016/j.ejca.2014.08.008) (PMID:25441408)

MacPherson, I. R. et al. (2014) CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 127(18), pp. 3893-3901. (doi:10.1242/jcs.135947) (PMID:25015290)

Macpherson, I.R. , Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi:10.1016/j.clbc.2014.09.009) (PMID:25454689)

Shepherd, S. T.C., Gillen, G., Morrison, P., Forte, C., MacPherson, I. R. , White, J. D. and Mark, P. B. (2014) Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. European Journal of Cancer, 50(5), pp. 944-952. (doi:10.1016/j.ejca.2013.12.021)

Macagno, J. P., Diaz Vera, J., Yu, Y., MacPherson, I. , Sandilands, E., Palmer, R., Norman, J. C. , Frame, M. and Vidal, M. (2014) FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genetics, 10(3), e1004262. (doi:10.1371/journal.pgen.1004262)

Shepherd, S. T.C., Macpherson, I. R. , White, J. D. and Mark, P. B. (2014) Response to: ‘Letter to the editor, European Journal of Cancer’, commenting on ‘Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma’. European Journal of Cancer, 25(7), pp. 1497-1503. (doi:10.1016/j.ejca.2014.04.027)

2013

Macpherson, I.R. , Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A. and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49(4), pp. 782-789. (doi:10.1016/j.ejca.2012.09.036)

2012

Yu, X. et al. (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 199(3), pp. 527-544. (doi:10.1083/jcb.201203025)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi:10.1016/j.devcel.2011.11.008)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12(536), (doi:10.1186/1471-2407-12-536)

2010

MacPherson, I.R.J. , Lindsay, C. and Canney, P. (2010) Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer: Targets and Therapy, 2010(2), pp. 59-70. (doi:10.2147/BCTT.S11835)

2009

Demetri, G. D., Lo Russo, P., MacPherson, I. R.J. , Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agarwal, S., Voi, M. and Evans, T.R. J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15(9), pp. 6232-6240. (doi:10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J. and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009(1), pp. 1-18. (doi:10.2147/BCTT.S6127)

Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi:10.2217/FON.09.18)

MacPherson, I.R.J. , Lindsay, C.R. and Reed, N.S. (2009) Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. Therapeutics and Clinical Risk Management, 2009(5), pp. 261-270. (doi:10.2147/TCRM.S3320)

2008

MacPherson, I. and Cassidy, J. (2008) Challenges in combinational oncology studies. Pharmaceutical Medicine, 22(2), pp. 85-97.

2007

MacPherson, I. , Hooper, S., Serrels, A., McGarry, L., Ozanne, B., Harrington, K., Frame, M., Sahai, E. and Brunton, V. (2007) p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. Oncogene, 26(36), pp. 5214-5228. (doi:10.1038/sj.onc.1210334)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi:10.2174/1874079000701010009)

2006

Serrels, A., MacPherson, I.R.J. , Evans, T.R.J. , Lee, F.Y., Clark, E.A., Sansom, O.J. , Ashton, G.H., Frame, M.C. and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5(12), pp. 3014-3022. (doi:10.1158/1535-7163.MCT-06-0382)

2004

Brunton, V.G., MacPherson, I.R.J. and Frame, M.C. (2004) Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochimica et Biophysica Acta: Molecular Cell Research, 1692(02-Mar), pp. 121-144. (doi:10.1016/j.bbamcr.2004.04.010)

2003

White, J., MacPherson, I. and Evans, T. (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10(1), pp. 249-251.

This list was generated on Sun Dec 16 16:53:18 2018 GMT.
Number of items: 36.

Articles

Copson, E. et al. (2018) The presentation, management and outcome of inflammatory breast cancer cases in the UK: data from a multi-centre retrospective review. Breast, 42, pp. 133-141. (doi:10.1016/j.breast.2018.09.003) (PMID:30278369)

Novo, D. et al. (2018) Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 9, 5069. (doi:10.1038/s41467-018-07339-y) (PMID:30498210) (PMCID:PMC6265295)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R. and Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicological Sciences, 163(1), pp. 293-306. (doi:10.1093/toxsci/kfy035) (PMID:29462473) (PMCID:PMC5920327)

Dornier, E. et al. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 8(1), 2255. (doi:10.1038/s41467-017-02101-2) (PMID:29269878) (PMCID:PMC5740148)

Hall, P. S. et al. (2017) Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA prelim trial. Value in Health, 20(10), pp. 1311-1318. (doi:10.1016/j.jval.2017.04.021) (PMID:29241890)

Cain, H., MacPherson, I.R. , Beresford, M., Pinder, S.E., Pong, J. and Dixon, J.M. (2017) Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clinical Oncology, 29(10), pp. 642-652. (doi:10.1016/j.clon.2017.06.003) (PMID:28669449)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi:10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Diaz-Vera, J., Palmer, S., Hernandez-Fernaud, J. R., Dornier, E., Mitchell, L. E., MacPherson, I. , Edwards, J. , Zanivan, S. and Norman, J. C. (2017) A proteomic approach to identify endosomal cargoes controlling cancer invasiveness. Journal of Cell Science, 130(4), pp. 697-711. (doi:10.1242/jcs.190835) (PMID:28062852)

Kristeleit, H., Parton, M., Beresford, M., Macpherson, I. R. , Sharma, R., Lazarus, L. and Kelleher, M. (2016) Long-term follow-up data from pivotal studies of adjuvant trastuzumab in early breast cancer. Targeted Oncology, 11(5), pp. 579-591. (doi:10.1007/s11523-016-0438-5) (PMID:27181019) (PMCID:PMC5054055)

Bartlett, J. M. S. et al. (2016) Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others. Journal of the National Cancer Institute, 108(9), djw050. (doi:10.1093/jnci/djw050) (PMID:27130929)

Marshall-Mckenna, R. , Morrison, A., Stirling, L., Hutchison, C., Rice, A.M., Hewitt, C., Paul, L., Rodger, M., MacPherson, I. and McCartney, E. (2016) A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Supportive Care in Cancer, 24(4), pp. 1821-1829. (doi:10.1007/s00520-015-2967-3) (PMID:26446702)

Palmieri, C. et al. (2016) Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget, 7(11), pp. 13209-13220. (doi:10.18632/oncotarget.4801) (PMID:26334099)

Argilés, G. et al. (2015) Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: a phase II trial. European Journal of Cancer, 51(8), pp. 942-949. (doi:10.1016/j.ejca.2015.02.013) (PMID:25818084)

Hickish, T. et al. (2014) A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50(18), pp. 3136-3144. (doi:10.1016/j.ejca.2014.08.008) (PMID:25441408)

MacPherson, I. R. et al. (2014) CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science, 127(18), pp. 3893-3901. (doi:10.1242/jcs.135947) (PMID:25015290)

Macpherson, I.R. , Bray, C.A., Hopkins, C., Hannon, R.A., Lewsley, L.A., Ritchie, D.M. and Canney, P. (2014) Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer. Clinical Breast Cancer, 15(2), pp. 117-127. (doi:10.1016/j.clbc.2014.09.009) (PMID:25454689)

Shepherd, S. T.C., Gillen, G., Morrison, P., Forte, C., MacPherson, I. R. , White, J. D. and Mark, P. B. (2014) Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. European Journal of Cancer, 50(5), pp. 944-952. (doi:10.1016/j.ejca.2013.12.021)

Macagno, J. P., Diaz Vera, J., Yu, Y., MacPherson, I. , Sandilands, E., Palmer, R., Norman, J. C. , Frame, M. and Vidal, M. (2014) FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genetics, 10(3), e1004262. (doi:10.1371/journal.pgen.1004262)

Shepherd, S. T.C., Macpherson, I. R. , White, J. D. and Mark, P. B. (2014) Response to: ‘Letter to the editor, European Journal of Cancer’, commenting on ‘Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma’. European Journal of Cancer, 25(7), pp. 1497-1503. (doi:10.1016/j.ejca.2014.04.027)

Macpherson, I.R. , Poondru, S., Simon, G.R., Gedrich, R., Brock, K., Hopkins, C.A., Stewart, K., Stephens, A. and Evans, T.R.J. (2013) A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer, 49(4), pp. 782-789. (doi:10.1016/j.ejca.2012.09.036)

Yu, X. et al. (2012) N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 199(3), pp. 527-544. (doi:10.1083/jcb.201203025)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi:10.1016/j.devcel.2011.11.008)

Anthoney, D.A. et al. (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer, 12(536), (doi:10.1186/1471-2407-12-536)

MacPherson, I.R.J. , Lindsay, C. and Canney, P. (2010) Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. Breast Cancer: Targets and Therapy, 2010(2), pp. 59-70. (doi:10.2147/BCTT.S11835)

Demetri, G. D., Lo Russo, P., MacPherson, I. R.J. , Wang, D., Morgan, J. A., Brunton, V. G., Paliwal, P., Agarwal, S., Voi, M. and Evans, T.R. J. (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clinical Cancer Research, 15(9), pp. 6232-6240. (doi:10.1158/1078-0432.CCR-09-0224)

MacPherson, I.R.J. and Evans, T.R.J. (2009) New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin. Breast Cancer: Targets and Therapy, 2009(1), pp. 1-18. (doi:10.2147/BCTT.S6127)

Lindsay, C.R., MacPherson, I.R.J. and Cassidy, J. (2009) Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncology, 5(4), pp. 421-432. (doi:10.2217/FON.09.18)

MacPherson, I.R.J. , Lindsay, C.R. and Reed, N.S. (2009) Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. Therapeutics and Clinical Risk Management, 2009(5), pp. 261-270. (doi:10.2147/TCRM.S3320)

MacPherson, I. and Cassidy, J. (2008) Challenges in combinational oncology studies. Pharmaceutical Medicine, 22(2), pp. 85-97.

MacPherson, I. , Hooper, S., Serrels, A., McGarry, L., Ozanne, B., Harrington, K., Frame, M., Sahai, E. and Brunton, V. (2007) p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. Oncogene, 26(36), pp. 5214-5228. (doi:10.1038/sj.onc.1210334)

MacPherson, I. , Jones, R. and Evans, T. (2007) Clinical development of src family kinase inhibitors in malignant melanoma. Open Cancer Journal, 2007(1), pp. 9-20. (doi:10.2174/1874079000701010009)

Serrels, A., MacPherson, I.R.J. , Evans, T.R.J. , Lee, F.Y., Clark, E.A., Sansom, O.J. , Ashton, G.H., Frame, M.C. and Brunton, V.G. (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Molecular Cancer Therapeutics, 5(12), pp. 3014-3022. (doi:10.1158/1535-7163.MCT-06-0382)

Brunton, V.G., MacPherson, I.R.J. and Frame, M.C. (2004) Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochimica et Biophysica Acta: Molecular Cell Research, 1692(02-Mar), pp. 121-144. (doi:10.1016/j.bbamcr.2004.04.010)

White, J., MacPherson, I. and Evans, T. (2003) Auto-immune neutropenia occurring in association with malignant melanoma. Oncology Reports, 10(1), pp. 249-251.

Conference or Workshop Item

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) The NTOX-G12- A New Clinical Assessment Tool for Nail Problems as a Result of Taxane Chemotherapy Regimens. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

Morrison, A., Marshall-Mckenna, R. , Hutchison, C., MacPherson, I. , Rice, A.M. and McFadyen, A.K. (2018) Taxane Chemotherapy and Nail Toxicity in Women with Breast Cancer: An Evaluation of Interventions. 1st UK Interdisciplinary Breast Cancer Symposium, Manchester, UK, 15-16 Jan 2018. (Unpublished)

This list was generated on Sun Dec 16 16:53:18 2018 GMT.